The fallout continues for Transcept Pharmaceuticals (TSPT -7.6%) after the FDA's rejection of its insomnia drug Intermezzo last week. The company announced plans over the weekend to slash its workforce by 45%, phasing out a number of "non-essential" positions in order to reduce operating expenses.
The fallout continues for Transcept Pharmaceuticals (TSPT -7.6%) after the FDA's rejection of...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs